Please assess the completion status of the following clinical trial:

Trial Title: Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:~--Disease Characteristics--~* Patients with a diagnosis of Fanconi's anemia AND Aplastic anemia OR Myelodysplastic syndrome OR Acute leukemia with or without chromosomal anomalies Aplastic anemia as defined by having at least one of the following: Platelet count less than 20,000/mm3 Absolute neutrophil count less than 500/mm3 Hemoglobin less than 8 g/dL~* Myelodysplastic syndrome with multilineage dysplasia With or without chromosomal anomalies~* Hematologic malignancy (e.g., acute myeloid leukemia, acute lymphoblastic leukemia, or B-cell non-Hodgkin's lymphoma)~* No greater than 30% blasts in bone marrow or greater than 5% blasts in peripheral blood~* No active CNS leukemia at time of transplantation~* Must have an HLA A, B, DRB1 identical or 1 antigen mismatched related (nonsibling) or unrelated bone marrow, peripheral blood, or umbilical cord blood donor~--Prior/Concurrent Therapy--~* Radiotherapy: No prior radiotherapy that would preclude total body irradiation~* Surgery: Not specified~--Patient Characteristics--~* Performance status: Karnofsky 70-100% OR Lansky 50-100%~* Hematopoietic: See Disease Characteristics~* Hepatic: No hepatic failure (e.g., coagulopathy or ascites)~* Renal: Creatinine clearance at least 40 mL/min~* Cardiovascular: Ejection fraction at least 45%~* Other: No active uncontrolled infection within one week of transplantation No malignant solid tumor (e.g., squamous cell carcinoma of the head, neck, or cervix) within 2 years of transplantation Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception

- Gender: ALL
- Minimum Age: 0 Years
- Maximum Age: 34 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).